South San Francisco, CA based CytomX Therapeutics [CTMX], a longstanding client of Occam Global’s, has strengthened its leadership team with the appointment of Jeff Landau as SVP, Head of Strategy and Chief Business Officer. CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. The company is developing a novel class of investigational conditionally activated therapeutics, based on its Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
Jeff Landau has over 20 years of biopharmaceutical experience in corporate development, corporate strategy, and new product strategy/planning. Most recently, he was SVP Corporate Development, Commercial and New Product Strategy at Catalyst Biosciences, Inc., where he was responsible for partnering, license and acquisition, corporate strategy, pipeline and new product planning, and alliance and project management. Prior to joining Catalyst, Jeff held corporate development and global product and pipeline strategy roles of increasing responsibility at Threshold Pharmaceuticals and Onyx Pharmaceuticals (acquired by Amgen). Jeff holds a BS in Biochemistry/Biotechnology from Virginia Polytechnic Institute and an MBA from Stanford Graduate School of Business.
Recently, Occam also placed Chau Cheng, PhD as VP, Investor Relations & Corporate Communications at CytomX. Previously, Chau led investor relations at Immunomedics, Inc. for over 15 years until the company’s acquisition by Gilead Sciences for $21B.
KalVista Pharmaceuticals (NASDAQ: KALV), a pharmaceutical company which has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME), has announced the appointment of Paul Audhya, MD as its Chief Medical Officer. Dr. Audhya has over 20 years of clinical development and global medical affairs leadership experience across a range of therapeutic areas and disciplines, including rare disease.
Most recently, Dr. Audhya was Senior Vice President, Global Medical Affairs at Arena Pharmaceuticals, Inc., where he established and provided oversight for all medical affairs functions including Health Economics and Outcomes Research and Global Patient Advocacy. Prior to that, he was Vice President, Global Strategy and Phase 4, Global Medical Affairs at Vertex Pharmaceuticals, Inc., where he led global launch and lifecycle management planning and implementation for the cystic fibrosis portfolio. Before Vertex, Dr. Audhya was Vice President, Medical Affairs at Hospira Inc. (acquired by Pfizer) where he introduced transformational strategies for biosimilars globally and led the successful launch of the first monoclonal biosimilar in the EU. In the years prior to Hospira, Dr. Audhya held positions of increasing responsibility across all stages of drug development at Reata Pharmaceuticals, Abbott Laboratories, Amgen, Bristol Myers Squibb and Janssen.
Dr. Audhya received a BA and MD from New York University, an MBA from Pepperdine University, and completed his residency in Internal Medicine at the University of Medicine and Dentistry of New Jersey.
Krakow, Poland based Ryvu Therapeutics has strengthened its leadership team with the appointment of Vatnak Vat-Ho as its Chief Business Officer and first US-based employee. Publicly traded on the Warsaw Stock Exchange, Ryvu (WSE: RVU) is a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology.
Vatnak will have accountability for Ryvu‘s corporate and business development efforts including strategic positioning, partnering discussions, and investor interactions. He will be instrumental in cementing Ryvu‘s role as an integral player in the US and global biotech ecosystem, as the company has secured multiple partnerships internationally but has yet to break into the US market.
Vatnak’s early career was in healthcare equity research. Subsequently, during an eight-year tenure at Pfizer, he held roles of increasing responsibility in oncology business development. He then moved to biotech as Vice President of Business Development at Affimed Inc. where he led partnering activities across both the preclinical and clinical pipeline. Vatnak holds an AB in Biology from Harvard University and an MBA from NYU’s Stern School of Business.
Based in Austin, TX, Triumvira Immunologics is a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers.
Teresa McRoberts brings more than four decades of experience in the financial sector across both the buy-side and sell-side with a focus on healthcare. Prior to joining Triumvira, she was Portfolio Manager, Senior Vice President and Senior Analyst at Alger Management, a growth-style investment management company, where she grew Alger’s Health Sciences Trust into a top 10% healthcare mutual fund. She was also previously Portfolio Manager at Morgan Stanley, Portfolio Co-Manager at Tribeca Global Management, a hedge fund owned by Citigroup, and an analyst and investment banker with J.P. Morgan. Ms. McRoberts holds a Master of Business Administration from Columbia Business School and Bachelor of Arts in English from Oberlin College.
MPM Capital is a leading biotechnology investment firm investing in early-stage therapeutics companies. David S. Bredt, MD, PhD, has joined its team of Executive Partners.
Before joining MPM, David was Site Head for Johnson & Johnson’s R&D Campus in La Jolla, which focuses on Neuroscience, Immunology and Biotechnology and is the original JLABS incubator for emerging healthcare companies. He was Global Head of Neuroscience Discovery at Johnson & Johnson where he had line management responsibility for neuroscience biology, biomarkers, and external innovation activities. His discovery group delivered numerous small and large molecule clinical candidates for Alzheimer’s disease, major depression, schizophrenia and epilepsy.
David joined Eli Lilly and Company as Vice President of Integrative Biology in August 2004 and became Vice President of Neuroscience Discovery and Early Development a few years later. As head of neuroscience research at Eli Lilly, David’s group was responsible for Discovery through Phase 2 programs in Neurology, Psychiatry, Migraine, and Pain indications. His group prosecuted numerous small and large molecules that entered preclinical and clinical development including galcanezumab / Emgality, which is now approved for preventative treatment of migraine.
"Occam has been a formidable recruiting partner for Recursion. Over the past three years, they have helped us make key additions to the senior executive team and Board. The firm has consistently provided a unique blend of nuanced and ethical judgement, tireless and creative effort, and strategic insight in helping us develop a holistic organizational plan as Recursion has evolved."Find out more Read the Case Study
"Bill Holodnak’s deep understanding of humanity allows him to match people and opportunities in a magical, almost musical way. In other words, it’s jazz baby."Find out more
"Occam has been a great and valued recruiting partner for Lux. They impress with business moxie, psychological acuity, ruthless objectivity and speed. A team and search firm apart."Find out more
"Occam brings an uncommon mix of intelligence, discipline and instinct to executive recruiting. Building companies is more art than science; they bring both to the party. In enduring fashion, Occam has mastered the human side of venture capital."Find out more
“Thorough, tireless, and professional, and they listen. Occam is a search firm that matches the entrepreneurial intensity of its clients. Results delivered with intelligence, urgency and style.”Find out more
Occam Global is a strategic human capital advisory firm dedicated to rigorous objectivity and enlightened aggression in executive recruiting and organizational development.
Our mission is to work selectively with exceptional clients for the long term. If candor and completeness is your preference in matters of Human Capital, the most opaque of asset classes, Occam is the partner for you.
The medieval philosopher William of Occam is the firm’s adopted patron saint. William spoke plainly and thought with rigor and humanity. These qualities yielded elevated ideas and also got him into a few punch-ups with the Holy See. His enduring concept, Occam’s Razor—“Lex Parsimoniae”—embodies an unrelenting focus on essentials in problem solving. His and our solutions strive for elegant simplicity.
Occam’s commitment is to provide an abundance of precisely qualified candidates through an open inquiry; due diligence for selection; and guidance on closure and integration. Our approach is relationship rather than transaction-driven.
Occam works with a wide range of high-growth industries as a trusted partner in executive recruitment.
Industry insights, client successes, and a deeper dive into the world of executive search and C-suite recruiting.View all news